Pregledni rad
https://doi.org/10.21857/yl4okf5lg9
CAR T Cell Therapy in Hematology: Navigating Toxicities and Deciphering Patient Experiences Through Patient-Reported Outcomes
Tamara Vasilj
orcid.org/0009-0005-8593-0622
; National Institutes of Health, National Cancer Institute, Center for Cancer Research, Immune Deficiency Cellular Therapy Branch, Myeloid Malignancies Program, Bethesda, Maryland, USA
*
Noa G Holtzmann
; University of Miami Miller School of Medicine, Department of Medicine, Division of Transplantation and Cellular Therapy, Miami, Florida, USA
Stevan Pavletic
; National Institutes of Health, National Cancer Institute, Center for Cancer Research, Immune Deficiency Cellular Therapy Branch, Myeloid Malignancies Program, Bethesda, Maryland, USA
* Dopisni autor.
Sažetak
This review examines the role of Patient-Reported Outcomes (PROs) in measuring toxicities of Chimeric Antigen Receptor T Cell Therapy (CAR T) for hematological malignancies. While highlighting the complex task of understanding the pathophysiology of CAR T’s unique adverse events (AEs), the discussion focuses on the need for precise characterization of the diverse symptomatology associated with individual CAR T syndromes and the importance of capturing patient experiences with these side effects using PRO instruments. This review underscores the continuous search for an ideal PRO tool that is effective in detecting both early changes and late toxicities; stressing the importance of monitoring PROs soon after therapy to gather data on acute toxicity, enabling timely interventions that could reduce symptom severity. The assessment of PROs at later stages is also highlighted as crucial for evaluating long-term quality of life (QoL), especially in terms of neurocognitive effects. The narrative review identifies a gap in current PRO tools not specifically tailored for CAR T therapy and calls for further research to develop a comprehensive set of symptoms for monitoring in various studies. Such efforts are vital for improving our understanding of therapy tolerability as well as for improving the treatment of these side effects. This would also enable the comparison of different CAR T products based on their response rates.
Ključne riječi
Immunotherapy; Adoptive; Patient Reported Outcome Measures; Hematologic neoplasms; Drug-related Side Effects and Adverse Reactions
Hrčak ID:
312720
URI
Datum izdavanja:
22.12.2023.
Posjeta: 548 *